Biosphere Medical Inc

Biosphere Medical — Investor Presentation (January 2010)

25 slides from Biosphere Medical's investor presentation, Jan 11, 2010

  1. Slide 1: BioSphere Medical January 2010

    BioSphere’ Qiioverere January 2010

  2. Slide 2: Safe Harbor

    SAFE HARBOR This presentation contains statements about the Company’s future expectations, plans and prospects that constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company’s strategic goals and objectives

  3. Slide 3: Company Snapshot

    COMPANY SNAPSHOT Embosphere - FDA 510(k) for hypervascularized tumors and AVMs 2000 2002 2005 2006 2007 2008 2009 Embosphere 510(k) UFE indication Sales Force expansion QuadraSphere 510(k) HepaSphere CE Mark - drug delivery of doxorubicin to treat HCC ACOG LEVEL A recommendation Distribution agreeme

  4. Slide 4: Investment Considerations

    INVESTMENT CONSIDERATIONS Platform technology applicable to multiple therapeutic areas with compelling market sizes Uterine fibroids (interventional gynecology); $650 million market (US, EMEA, China, Japan, Brazil) Primary liver cancer (interventional oncology); $380 million market for drug-eluting

  5. Slide 5: Differentiated Proprietary Products – Dominant Market Share

    DIFFERENTIATED PROPRIETARY PRODUCTS – DOMINANT MARKET SHARE EMBOSPHERE MICROSPHERES First embolic cleared by the FDA for UFE Most clinically studied spherical embolic Calibrated sphere/targeted delivery Hydrophilic/lubricious/non-aggregating Compressible and resilient formulation Positive polymer ch

  6. Slide 6: Marketed Products and Pipeline

    PRODUCT ACTUAL / PLANNED INDICATIONS PRECLINICAL CLINICAL MARKETED Embosphere Microspheres Uterine Fibroid Embolization HepaSphere / QuadraSphere Microspheres Hypervascularized tumors and AVMs HepaSphere Microspheres + Doxorubicin Hepatocellular Carcinoma (HCC) QuadraSphere Microspheres – US IDE sub

  7. Slide 7: Current Therapeutic Focus; Pipeline

    CURRENT THERAPEUTIC FOCUS; PIPELINE Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Interventional Urology – Treatment of benign prostat

  8. Slide 8: Market for Women with Symptomatic Fibroids

    MARKET FOR WOMEN WITH SYMPTOMATIC FIBROIDS Millions Millions Women 30-49 Years Old

  9. Slide 9: Clinical Results of UFE

    CLINICAL RESULTS OF UFE Uterus-sparing, safe and effective symptom relief (2003-2008) ACOG Level A Recommendation Reproducible quality-of-life outcomes FIBROID Registry (December 2005, January 2008) 5-year durability (November 2005) Fertility “Pregnancy possible after UFE” (January 2005, November 20

  10. Slide 10: Patient - Provider - Supplier Perspectives

    PATIENT - PROVIDER - SUPPLIER PERSPECTIVES DAYS DAYS HOSPITAL UFE performed in a cath lab, a lower cost venue than the operating room CMS 2010 reimbursement up 7.6% to ~ $6,413 per procedure Average contribution margin to hospital $2,860 vs. $163 for hysterectomy and $(9) for myomectomy INTERVENTION

  11. Slide 11: Pioneer/Leader in Embolotherapy

    PIONEER/LEADER IN EMBOLOTHERAPY Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Interventional Urology – Treatment of benign prostatic h

  12. Slide 12: Building a Global Position in Interventional Oncology

    BUILDING A GLOBAL POSITION IN INTERVENTIONAL ONCOLOGY ~24% of current embolic sales Growing global incidence of primary liver cancer (HCC) ~600,000 new cases worldwide each year Half WW incidence is in China Worldwide adoption of Embosphere Microspheres for multiple-treatment protocols Shipments to

  13. Slide 13: Chemoembolization Is Standard of Care

    “Chemoembolization is accepted worldwide as an effective treatment for patients with unresectable HCC and adequate preservation of liver function.” Brown, et al., Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies, JVIR 2006; 17(2):217-223. CHEMOEMBOL

  14. Slide 14: HepaSphere/QuadraSphere – Drug Delivery

    In vivo evaluation of drug release: Immunofluorescence showing doxorubicin released in the tissue surrounding the microspheres HEPASPHERE/QUADRASPHERE – DRUG DELIVERY Doxorubicin-loaded Microspheres* Source: Interventional News (Jan-Mar, 2007), p. 6. *CE Mark clearance for the delivery of doxorubici

  15. Slide 15: HepaSphere/QuadraSphere in Liver Cancer Treatment (HiQUALITY) Protocol

    HepaSphere/QuadraSphere in Liver Cancer Treatment (HiQUALITY) Protocol QuadraSphere loaded with doxorubicin vs. conventional transarterial chemoembolization (cTACE) with doxorubicin; current standard of care 200+ patients at 16 sites in the US, European Union and Brazil Primary endpoint/basis PMA fi

  16. Slide 16: Clinical Basis for HiQUALITY Study

    CLINICAL BASIS FOR HiQUALITY STUDY Maurizio Grosso, MD 34 patients with primary liver cancer demonstrated an objective tumor response of 79% at six months when treated with HepaSphere Microspheres loaded with doxorubicin Guido Poggi, MD Investigated new use for HepaSphere: With oxaliplatin for intra

  17. Slide 17: Pioneer/Leader in Embolotherapy

    PIONEER/LEADER IN EMBOLOTHERAPY Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Current Therapeutic Focus Interventional Urology – Treat

  18. Slide 18: BPH Opportunity U.S. Only

    Millions Estimated market opportunity if actively treated patients receive 1 embolization cycle +$800 million BPH OPPORTUNITY U.S. ONLY

  19. Slide 19: BPH Preclinical Studies

    MRI scan of the prostate (arrow) MRI scan of the prostate (arrow) 1 month prior to embolization with 500- after embolization with 500-700µm 700µm Embospheres Embospheres: 50% volume reduction Mild decrease in urethral stenosis after embolization Results: 3T MRI scans before and 1 month after emboliz

  20. Slide 20: BPH Clinical Update

    Clinical Studies Initial clinical results (2 patients using 300-500µm Embosphere) Each patient exhibited marked (40% and 24%, respectively, at one month, and 48% and 28%, respectively, at 6 months) reduction in prostate volume post procedure by MRI Both patients enjoyed improvement in symptoms with

  21. Slide 21: Experienced Executive Leadership Team

    EXPERIENCED EXECUTIVE LEADERSHIP TEAM Richard J. Faleschini, President and Chief Executive Officer American Medical Systems, Medtronic, Cordis Martin J. Joyce, Exec. Vice President, Chief Financial Officer Stratex Group, Serono, Millipore Melodie R. Domurad, PhD, Vice President of Regulatory, Medica

  22. Slide 22: 2010 Strategic Priorities

    2010 STRATEGIC PRIORITIES Interventional Gynecology Scale-up community health talks in 2010 to over ~200+ events Commence direct-to-employer education for UFE promoting the rapid return to work after a UFE procedure compared to surgical alternatives Interventional Oncology Based on the green light f

  23. Slide 23: Financial Update

    FINANCIAL UPDATE (In thousands, except per-share amounts) Sept 30, 2009 Dec 31, 2008 Cash, short- and long-term investments $18,566 $18,239 Total Assets $30,568 $30,228 Sept 30, 2009 Sept 30, 2008 Revenue $7,686 $7,198 Net Loss Applicable to Common Stockholders ($361) ($1,543) Basic and Diluted Net

  24. Slide 24: Investment Considerations

    INVESTMENT CONSIDERATIONS Platform technology applicable to multiple therapeutic areas with compelling market sizes Uterine fibroids (interventional gynecology); $650 million market (US, EMEA, China, Japan, Brazil) Primary liver cancer (interventional oncology); $380 million market for drug-eluting

  25. Slide 25: BioSphere Medical

    BioSphere’ Qiioverere January 2010

BioSphere Medical — Investor Presentation (January 2010) on 6ix